Blog
RSS FeedPosted by Michael Wonder on 07 Sep 2023
Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease
7 September 2023 - Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) has been approved by the MHRA as a treatment ...
Posted by Michael Wonder on 06 Sep 2023
Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy
6 September 2023 - NICE has published final evidence-based recommendations on the use of mavacamten (Camzyos) for the treatment of ...
Posted by Michael Wonder on 06 Sep 2023
MHRA approves Pfizer/BioNTech’s adapted COVID-19 vaccine (Comirnaty) that targets Omicron XBB.1.5
5 September 2023 - Approval has today been granted by the MHRA for an adapted Pfizer/BioNTech COVID-19 vaccine that targets ...
Posted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in ...
Posted by Michael Wonder on 05 Sep 2023
Aquipta (atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults
4 September 2023 - The marketing authorisation is based on results from two pivotal Phase 3 studies in which the treatment ...
Posted by Michael Wonder on 01 Sep 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis
1 September 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Aug 2023
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies
30 August 2023 - As global drug development re-equilibrates following the COVID-19 pandemic, the number of new oncology drugs approved by ...
Posted by Michael Wonder on 29 Aug 2023
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
29 August 2023 - Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types ...
Posted by Michael Wonder on 23 Aug 2023
Dupilumab for the treatment of patients with prurigo nodularis
23 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Aug 2023
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
18 August 2023 - Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder ...
Posted by Michael Wonder on 17 Aug 2023
Amicus Therapeutics announces approval and launch of new Pompe disease therapy in the United Kingdom
15 August 2023 - Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) approved for adults living with late-onset Pompe disease in Great Britain. ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 15 Aug 2023
Cipaglucosidase alfa and miglustat for the treatment of patients with late-onset Pompe disease
15 August 2023 - NICE has published evidence-based recommendations on the use of cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for ...
Posted by Michael Wonder on 08 Aug 2023
UKHSA unveils VDEC in ‘step change’ for UK’s growing vaccine capabilities
7 August 2023 - Vaccine Development and Evaluation Centre to be at forefront of UK’s ability to research and develop vaccines ...
Posted by Michael Wonder on 07 Aug 2023
GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran
1 August 2023 - Local GP leaders across the south of England have told practices not to follow the NHS’s ...